FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

[News]

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

More... (http://www.news-medical.net/news/20110829/FDA-approves-Abbotts-Vysis-ALK-FISH-test-for-NSCLC-therapy-selection.aspx)